Grow Your Pharma Business Digitally
Weekly News Recap #Phispers
Stock Recap #PipelineProspector
Check COS databaseCheck USDMF database
Contact UsPharmaScopic.com
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AD101
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharma Company AmyriAD Steps into the Light with Phase III Symptom Relief Drug for Alzheimer's Disease
Details : AD101 was initially discovered in phenotypic testing of animal models of learning and memory. It also improved learning and memory in models dependent on Aβ and tau while reducing the accumulation of both biomarkers in these animals.
Brand Name : AD101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 10, 2021
Highest Development Status : Phase II
Stock Recap#PipelineProspector
Data Compilation#PharmaFlow
Virtual Booth